ClinicalTrials.Veeva

Menu

Feasibility Study of PrePex Device When Performed on Early Infants & Children Male Population by Physicians (RMC-06)

M

Ministry of Health, Rwanda

Status

Completed

Conditions

Medical Device Complication

Treatments

Device: Male circumcision using a non-surgical device

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The PrePex is a WHO prequalified medical device for adult male circumcision for HIV prevention. The Government of Rwanda was the first country to implement the PrePex and acts as the leading Center of Excellence providing training and formal guidelines.

In support of efforts to scale up male circumcision, readily available data have been applied to estimate the potential cost and impact of scaling up medical MC services in Rwanda to reach 80 percent of adult, children and newborn males by 2015. Infant and children male circumcision ensures that the wound will be healed before sexual activity begins, and thus reduces the risk of HIV transmission during healing period.

Full description

The American Academy of Pediatrics (AAP) published in August 2012 a technical report and a policy statement, "Evaluation of current evidence indicates that the health benefits of new-born male circumcision outweigh the risks; furthermore, the benefits of newborn male circumcision justify access to this procedure for families who choose it. Specific benefits from male circumcision were identified for the prevention of urinary tract infections, acquisition of HIV, transmission of some sexually transmitted infections, and penile cancer. Male circumcision does not appear to adversely affect penile sexual function/sensitivity or sexual satisfaction. It is imperative that those providing circumcision are adequately trained and that both sterile techniques and effective pain management are used. Significant acute complications are rare."

The primary objective of the study was to assess the safety and efficacy of the PrePex device among healthy early infant and children males scheduled for voluntary circumcision. The study consisted of 2 phases:

Phase I included infants age 5-33 days Phase II included children age 4-10 years.

The study examined the feasibility of performing PrePex circumcision on early infants and children male population.

Enrollment

60 patients

Sex

Male

Ages

5 days to 10 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Early infants and children males in ages - 5 to 33 days or 4-10 years
  • Weighs more than 2500gr (for early infants)
  • The infant or child should be healthy and in full-term
  • Parent/legal guardian consent to the circumcision procedure
  • Uncircumcised
  • Parent/legal guardian able to understand the study procedures and requirements
  • Parent/legal guardian agree to keep the infant for 48 hours or child for 24 hours hospitalization
  • Parent/legal guardian agree to return to the health care facility for follow-up visits (or as instructed) after his circumcision until complete healing is achieved
  • Parent/legal guardian able to comprehend and freely give informed consent for participation in this study and is considered by the investigator to have a good compliance for the study
  • Parent/legal guardian agrees to anonymous video and photographs of the procedure and follow up visits.

Exclusion criteria

  • Parent/legal guardian withhold consent
  • Active genital infection, anatomic abnormality or other condition, which in the opinion of the investigator prevents the participant from undergoing a circumcision
  • Participant with the following diseases/conditions: Bilateral hydroceles, Curvature with penile torsion, Absence of ventral foreskin, Concealed penis (trapping urine beneath the foreskin), Megalourethra with deficiency of corpus spongiosum, Penoscrotal webbing, Epispadias, dorsal curvature, Hypospadias, Phimosis, paraphimosis, warts under the prepuce, torn or tight frenulum, narrow prepuce, hypospadias, epispadias, known haematological disorders and jaundice, yellow sclera or purpuric skin lesions, congenital abnormality
  • Known bleeding / coagulation abnormality, uncontrolled diabetes
  • Participant that to the opinion of the investigator is not a good candidate
  • Parent/legal guardian does not agree to anonymous video and photographs of the procedure and follow up visits.

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Early ifants
Experimental group
Description:
Intervention Male circumcision using a non-surgical device
Treatment:
Device: Male circumcision using a non-surgical device
Cildren
Experimental group
Description:
Intervention Male circumcision using a non-surgical device
Treatment:
Device: Male circumcision using a non-surgical device

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems